Establishment and Evaluation of Prognostic Prediction Model for Diffuse Large B-cell Lymphoma Patients Based on International Prognostic Index and FAT4, TP53 Mutation.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a common type of non-Hodgkin lymphoma with clinical and genetic heterogeneity, leading to significant differences in patient prognosis. In this study, a retrospective analysis was conducted on relevant data from 155 DLBCL patients treated at our hospital. Single-factor and further multivariate COX analysis were used to identify independent prognostic factors associated with progression-free survival (PFS) and overall survival (OS) in DLBCL patients. The predictive performance and clinical application value of the risk prediction model were evaluated using receiver operating characteristic (ROC) curves and decision curve analysis (DCA). The consistency between the actual and predicted event rates was assessed using calibration plots, and validation was performed using bootstrapping resampling. It was demonstrated that the integration of FAT4 mutation and TP53 mutation into the FAT4-TP53-IPI model can enhance the prognostic value of the IPI scoring system.